References

Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. N Engl J Med 295:237-241,1976.

Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 85: 155-160,1976.

Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Seshadri P, Chesterman CN, Australian HIT Study Group. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 86:1170-1175, 2001.

Doty JR, Alving BM, McDonnell DE, Ondra SL. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery 19:69-72,1986.

Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85:950-957, 2001.

Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocy-topenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851, 2000.

Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombo-cytopenia: an analysis of treatment failures. Eur J Haematol 7:109-113, 2003.

Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 7:667-672,1988.

Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843, 2001.

Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129:1407-1416, 2006.

Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759-765, 2006.

Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractio-nated heparin and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710-2715, 2005.

Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia. Eur J Haematol 72:366-369, 2004.

Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomized controlled trials. BMJ 316:969-975, 1998.

Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg 186:752-758, 1977.

Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 164:1961-1964, 2004.

Rice L, Jackson D. Can heparin cause clotting? Heart Lung 10:331-335, 1981.

Rice L, Huffman DM, Levine ML, Udden MM, Waddell CC, Luper WE. Heparin-induced thrombocytopenia/thrombosis syndrome: clinical manifestation and insights. Blood 68(suppl 1):339a, 1986.

Rice L, Huffman DM, Waddell CC, Luper WE, Udden MM, Levine ML. Therapy of thromboembolic disease: the heparin thrombocytopenia/thrombosis syndrome. In: Thrombosis, Anticoagulants and Antiplatelet Agents in Clinical Practice. New York: Park Row Publishers, 31-36,1988.

Rice L, Attisha W, Francis JL, Drexler AJ. Delayed onset heparin-induced thrombocyto-penia. Ann Intern Med 136:210-215, 2002.

Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR. Warfarin-induced skin necrosis and venous limb gangrene with heparin-induced thrombocytopenia. Arch Intern Med 164:66-70, 2004.

Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629-635, 1999.

Warkentin TE. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost 85:947-949, 2001.

Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535-555, 2003.

Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 356:891-893, 2007.

Warkentin TE, Berstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 348:1067-1069, 2003.

Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 suppl):311S-337S, 2004.

Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996.

Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001a.

Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502-506, 2001b.

Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocy-topenia. Ann Intern Med 127:804-812, 1997.

Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia. Arch Intern Med 163:2518-2524, 2003.

Warkentin TE, Cook RJ, Marder VJ, Sheppard JI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106: 3791-3796, 2005.

0 0

Post a comment